Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope B)
|Effective start/end date||3/1/15 → 5/1/22|
- NAT'L SURGICAL ADJ BREAST & BOWEL PROJ.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.